

# **Colorectal Cancer Canada**

**Financial Statements  
June 30, 2025**

**Crowe BGK S.E.N.C.R.L. | LLP**

Société de comptables professionnels agréés  
Partnership of Chartered Professional Accountants

# Colorectal Cancer Canada

## Financial Statements June 30, 2025

---

### Contents

Independent Auditor's Report	1 - 2
Statement of Financial Position	3
Statement of Operations and Changes in Net Assets	4
Statement of Cash Flows	5
Notes to Financial Statements	6 - 12

**Crowe BGK S.E.N.C.R.L. | LLP**

Société de comptables professionnels agréés  
Partnership of Chartered Professional Accountants

## **Independent Auditor's Report**

To the Members of  
Colorectal Cancer Canada

### *Qualified Opinion*

We have audited the financial statements of Colorectal Cancer Canada (the Organization), which comprise the statement of financial position as at June 30, 2025, and the statements of operations and changes in net assets and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the possible effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as at June 30, 2025, and its financial performance and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

### *Basis for Qualified Opinion*

In common with many charitable organizations, the Organization derives most of its revenue from donations and fundraising activities, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, verification of these revenues was limited to the amounts recorded in the records of the Organization. Therefore, we were not able to determine whether any adjustments might be necessary to the revenue, excess of revenues over expenses, and cash flows from operations for the year ended June 30, 2025, current assets and unrestricted net assets as at June 30, 2025. Our audit opinion on the financial statements for the year ended June 30, 2024 was modified accordingly because of the possible effects of this limitation in scope.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Organization in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified audit opinion.

### *Responsibilities of Management and Those Charged with Governance for the Financial Statements*

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Organization's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Organization or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Organization's financial reporting process.

### *Auditor's Responsibilities for the Audit of the Financial Statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Organization's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Organization to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

*Crowe BGK LLP.\**

Chartered Professional Accountants

Montréal, Québec  
November 13, 2025


\* By CPA auditor, public accountancy permit No. A133345

# Colorectal Cancer Canada

## Statement of Financial Position As at June 30, 2025

	2025 \$	2024 \$
<b>Assets</b>		
Current		
Cash and cash equivalents (note 3)	198,129	278,719
Marketable securities (note 4)	569,536	869,760
Accounts receivable (note 5)	132,396	80,732
Prepaid expenses	22,939	58,116
	923,000	1,287,327
Capital assets (note 6)	20,836	31,606
	943,836	1,318,933
<b>Liabilities</b>		
Current		
Accounts payable and accrued liabilities (note 7)	88,743	137,752
Deferred contributions (note 8)	171,770	181,126
	260,513	318,878
<b>Net assets</b>		
Unrestricted net assets	683,323	1,000,055
	943,836	1,318,933
Commitment (note 9)		

Approved on behalf of the Board:

 , Director

See accompanying notes.

# Colorectal Cancer Canada

## Statement of Operations and Changes in Net Assets For the Year Ended June 30, 2025

	2025 \$	2024 \$
<b>Revenue</b>		
Sponsorships	1,051,232	1,237,816
Donations	753,778	658,076
Tributes	37,004	73,300
Investment income	102,273	90,720
Other	44,129	18,720
	<b>1,988,416</b>	<b>2,078,632</b>
<b>Expenses</b>		
Salaries and wage levies (note 10)	1,071,560	982,450
Consulting fees	456,809	325,997
Accounting	76,229	59,079
Office and general	92,918	98,731
Rent	70,617	70,651
Travel	103,002	175,725
Professional fees	43,736	56,089
Advertising and promotion	166,861	219,487
Event supplies & rentals	107,032	149,668
Interests and bank charges	38,854	46,516
Computer and software expenses	45,105	32,326
Telephone	12,387	10,708
Amortization of capital assets	10,770	15,076
Insurance	9,268	10,034
	<b>2,305,148</b>	<b>2,252,537</b>
<b>Deficiency of revenues over expenses</b>	<b>(316,732)</b>	<b>(173,905)</b>
<b>Net assets, beginning of year</b>	<b>1,000,055</b>	<b>1,173,960</b>
<b>Net assets, end of year</b>	<b>683,323</b>	<b>1,000,055</b>

See accompanying notes.

# Colorectal Cancer Canada

## Statement of Cash Flows For the Year Ended June 30, 2025

	2025 \$	2024 \$
<b>Operating activities</b>		
Deficiency of revenues over expenses	(316,732)	(173,905)
Non-cash items:		
Amortization of capital assets	10,770	15,076
Unrealized gain on marketable securities on fair value adjustment	(52,942)	(50,158)
	(358,904)	(208,987)
Net change in non-cash items related to operating activities:		
Accounts receivable	(51,664)	2,926
Prepaid expenses	35,177	(8,612)
Accounts payable and accrued liabilities	(49,009)	(42,780)
Deferred contributions	(9,356)	(166,968)
	(433,756)	(424,421)
<b>Investing activities</b>		
Acquisition of capital assets	-	(10,777)
Net change in marketable securities	353,166	260,849
	353,166	250,072
<b>Financing activity</b>		
Repayment of long-term debt	-	(40,000)
<b>Decrease in cash and cash equivalents</b>	<b>(80,590)</b>	<b>(214,349)</b>
<b>Cash and cash equivalents, beginning of year</b>	<b>278,719</b>	<b>493,068</b>
<b>Cash and cash equivalents, end of year</b>	<b>198,129</b>	<b>278,719</b>

See accompanying notes.

# Colorectal Cancer Canada

## Notes to Financial Statements

June 30, 2025

---

### 1. Incorporation and nature of the organization

Colorectal Cancer Canada (the "Organization") operates as a registered charity and has continued under Section 211 of the Canada Not-for-Profit Corporations Act and is not subject to income tax.

The mission of the Organization is to support and improve the quality of life of Canadians with colorectal cancer as well as their families and caregivers. The Organization is dedicated to increasing awareness of colorectal cancer, supporting patients and advocating for population-based screening and timely access to effective treatments.

### 2. Significant accounting policies

The financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations (ASNPO) as issued by the Accounting Standards Board in Canada using the following significant accounting policies:

Revenue recognition:

The Organization follows the deferral method of accounting for contributions. Restricted contributions are recognized as revenue in the year in which the related expenses are incurred. Unrestricted contributions are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured. Endowment contributions are recognized as direct increases in net assets.

Investment income is recognized as revenue when it is earned on an accrual basis.

Pledges are recognized as revenue only when the amount can be reasonably estimated and collection is reasonably assured.

Contributed materials and services:

Contributions of materials are recognized as both contributions and expenses in the statement of operations when a fair value can be reasonably estimated and when the materials are used in the normal course of the Organization's operations and would otherwise have been purchased.

In the course of its activities, the Organization uses the services of volunteers. Due to the difficulty of determining their fair value, contributed services are not recognized in the financial statements.

Cash and cash equivalents:

Cash and cash equivalents include balances with banks and short-term investments which are not held for investment purposes and are readily convertible to a known amount of cash and subject to an insignificant risk of changes in value. The Organization has no restrictions on its cash and cash equivalents.

# Colorectal Cancer Canada

## Notes to Financial Statements

June 30, 2025

---

### 2. Significant accounting policies (continued)

Capital assets:

Capital assets are accounted for at cost. Amortization is calculated on their respective estimated useful life using the following methods and rates:

	Methods	Rates
Computer equipment	Declining balance	30%
Furniture and fixtures	Declining balance	20%
Telephone system	Declining balance	20%
Leasehold improvements	Straight-line	5 years

Impairment of long-lived assets:

Capital assets are tested for recoverability whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value.

Use of estimates:

The preparation of these financial statements in conformity with Canadian accounting standards for not-for-profit organizations requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the current period. Actual results could differ from the estimated amounts. These estimates are reviewed periodically and adjustments are made to income as appropriate in the year they become known. The main estimates relate to the useful life of capital assets, accrued liabilities and deferred contributions.

Financial instruments:

#### *Initial measurement*

The Organization initially measures its financial assets and liabilities originated or exchanged in arm's length transactions at fair value. Financial assets and liabilities originated or exchanged in related party transactions, except for those that involve parties whose sole relationship with the Organization is in the capacity of management, are initially measured at cost, with the exception of investments in equity instruments quoted in an active market, which are measured at fair value.

The cost of a financial instrument in a related party transaction depends on whether the instrument has repayment terms. The cost of a financial asset or liability in a related party transaction that has repayment terms is determined using its undiscounted cash flows, excluding interest and dividend payments, less any impairment losses previously recognized by the transferor. When the financial instrument does not have repayment terms, its cost is determined using the consideration transferred or received by the Organization in the transaction.

# Colorectal Cancer Canada

## Notes to Financial Statements June 30, 2025

---

### 2. Significant accounting policies (continued)

#### *Subsequent measurement*

The Organization subsequently measures all its financial assets and liabilities at cost or amortized cost, except for investments in equity instruments that are quoted in an active market, which are measured at fair value. Changes in fair value of these financial instruments are recognized in net income in the period incurred.

Financial assets measured at cost or amortized cost include cash and cash equivalents and accounts receivable.

Financial liabilities measured at cost or amortized cost include accounts payable and accrued liabilities.

Financial assets measured at fair value include marketable securities.

#### *Impairment*

For financial assets measured at cost or amortized cost, the Organization determines whether there are indications of possible impairment. When there are, and the Organization determines that a significant adverse change has occurred during the period in the expected timing or amount of future cash flows, a write-down is recognized in net income. If the indicators of impairment have decreased or no longer exist, the previously recognized impairment loss may be reversed to the extent of the improvement. The carrying amount of the financial asset may not be greater than the amount that would have been reported at the date of the reversal had the impairment not been recognized previously. The amount of the reversal is recognized in net income.

#### *Government assistance:*

Government assistance is recognized when there is reasonable assurance that it will be received and all related conditions will be complied with. When the government assistance relates to an expense item, it is recognized as a reduction of expense over the period necessary to match the government assistance on a systematic basis to the costs that it is intended to subsidize.

#### *Comparative figures:*

Certain prior year's accounts have been reclassified to conform with the presentation adopted in the current year

### 3. Credit facility

The Organization's credit facility arrangement consists of an unutilized demand loan in the amount of \$40,000. The loan bears interest at the bank's prime rate plus 1.55% per annum, is secured by the assets of the Organization and is reviewed on an annual basis.

# Colorectal Cancer Canada

## Notes to Financial Statements

June 30, 2025

### 4. Marketable securities

The marketable securities consist primarily of investments in equities, mutual funds and fixed income debentures with interest rates ranging from 3.95% to 6.98% and maturity dates varying from February 2029 to December 2043.

### 5. Accounts receivable

	2025 \$	2024 \$
Trade	104,600	3,907
Sales taxes receivable	27,796	76,825
	132,396	80,732

### 6. Capital assets

	Cost \$	Accumulated amortization \$	2025 Net book value \$	2024 Net book value \$
Computer equipment	110,718	105,480	5,238	11,639
Furniture and fixtures	53,706	43,153	10,553	13,191
Telephone system	22,339	20,419	1,920	2,400
Leasehold improvements	6,251	3,126	3,125	4,376
	193,014	172,178	20,836	31,606

### 7. Accounts payable and accrued liabilities

	2025 \$	2024 \$
Accounts payable	47,110	86,753
Accrued liabilities	35,895	47,517
Payroll taxes payable	5,738	3,482
	88,743	137,752

# Colorectal Cancer Canada

## Notes to Financial Statements

June 30, 2025

---

### 8. Deferred contributions

Deferred contributions consist of unspent contributions for various programs. Recognition of these amounts as revenue is deferred to periods when the expenditures relating to the specified programs are incurred.

Changes in the deferred contributions balance are as follows:

	2025 \$	2024 \$
Balance, beginning of year	181,126	348,094
Amount received during the year:	241,770	166,126
Less: Amounts recognized as revenue during the year	(181,126)	(333,094)
Balance, end of year	171,770	181,126

### 9. Commitment

The Organization has a lease agreement for their premises ending May 2028 and with minimum annual payments as follows:

	\$
2026	26,492
2027	28,900
2028	26,492
	81,884

# Colorectal Cancer Canada

## Notes to Financial Statements

June 30, 2025

---

### 10. Government assistance

During the year, the Organization received government subsidies in relation to the salaries and wage levies incurred by the Organization in its operations during the period July 1, 2024 to June 30, 2025. These subsidies reimburse a certain percentage of an intern's wages to an eligible employer during the program application period. There are no unfulfilled conditions attached to the subsidies recognized in income.

The government assistance recorded as reduction to salaries and wage levies include:

	\$
Canada Summer Jobs program	23,345
Accueillez un stagiaire	56,075
	79,420

### 11. Related party transactions

During the year, the Organization paid consulting fees of approximately \$318,000 (2024 - \$303,000) to a director. This transaction is measured at the exchange amount which is the amount established and agreed to by the related parties.

### 12. Financial instruments

Financial risks

The significant risks arising from financial instruments to which the Organization is exposed as at June 30, 2025 are detailed below.

Credit risk and economic dependence

Credit risk is the risk that one party to a financial asset will cause a financial loss for the Organization by failing to discharge an obligation. The Organization's credit risk is mainly related to accounts receivable.

Liquidity risk

Liquidity risk is the risk that the Organization will encounter difficulty in meeting obligations associated with financial liabilities. The Organization is exposed to this risk mainly in respect of its accounts payable and accrued liabilities. The Organization manages this risk by monitoring its operating requirements. The Organization prepares budgets and cash forecasts to ensure it has sufficient funds to fulfill its obligations.

# Colorectal Cancer Canada

## Notes to Financial Statements

June 30, 2025

---

### 12. Financial instruments (continued)

#### Market risk

Market risk is the risk that the fair value or future cash flows of the Organization's financial instruments will fluctuate because of changes in market prices. Some of the Organization's financial instruments expose it to this risk, which comprises currency risk, interest rate risk and other price risk. The Organization is mainly exposed to other price risk.

#### Other price risk

The Organization is exposed to other price risk through its marketable securities investments for which the value fluctuates with the quoted market price.